In a single-center study of 35 patients with resectable stage IIIA/IIIB NSCLC who received neoadjuvant pembrolizumab and chemotherapy, 51.43% patients achieved pCR and 74.29% patients achieved MPR, and PD-L1 expression (TPS with 50% threshold) in biopsy tumor tissue prior to treatment was not associated with neoadjuvant pathological response [11]. Here, CD274 is linked to non-small cell lung carcinoma.